The Efficacy and Safety of Mometasone Furoate Delivered via a Dry Powder Inhaler for the Treatment of Asthma

References

• Fuhlbrigge A L, Adams R J, Guilbert T W, Grant E, Lozano P, Janson S L, Martinez F, Weiss K B, Weiss S T. The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med 2002; 166: 1044–1049, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Juniper E F, Guyatt G H, Epstein R S, Ferrie P J, Jaeschke R, Hiller T K. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: 76–83, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. Asthma prevalence, health care use and mortality. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Bethesda, MD 2002, http://www.cdc.gov/nchs/products/ Available at pubs/pubd/hestats/asthma/asthma.htm. Accessed January 30, 2006
   Google Scholar
• 2004 Chartbook on Cardiovascular, Lung, and Blood Diseases. U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD, http://www.nhlbi.nih.gov/resources/docs/04_chtbk.pdf Accessed April 13, 2006 Available at
   Google Scholar
• National Asthma Education and Prevention Program (NAEPP). Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics 2002. National Heart, Lung, and Blood Institute, Bethesda, MD 2003, NIH Publication. 02-5074
   Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: updated 2005. National Heart, Lung, and Blood Institute, Bethesda, MD 2005, NIH Publication. 02-3659
   Google Scholar
• British Guideline on the Management of Asthma: revised ed. British Thoracic Society, Scottish Intercollegiate Guidelines Network, http://www.brit-thoracic.org.uk/asthma-guideline-download.html Available at Accessed May 6, 2006
   Google Scholar
• Bateman E D, Boushey H A, Bousquet J, Busse W W, Clark T JH, Pauwels R A, Pedersen S E. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836–844, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Nelson H S, Weiss S T, Bleecker E R, Yancey S W, Dorinsky P M. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15–26, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Advair Diskus (fluticasone propionate and salmeterol inhalation powder). GlaxoSmithKline, Research Triangle Park, NC 2006, Full Prescribing Information
   Google Scholar
• Serevent Diskus (salmeterol xinafoate inhalation powder). GlaxoSmithKline, Research Triangle Park, NC 2006, Full Prescribing Information
   Google Scholar
• Foradil Aerolizer (formoterol fumarate inhalation powder). Novartis Pharma AG/Schering Corporation, Kenilworth, NJ 2006, Full Prescribing Information
   Google Scholar
• Symbicort Inhalation Aerosol (budesonide/formoterol fumarate dihydrate). U.S. Food and Drug Administration, Rockville, MD, www.fda.gov/cder/foi/label/2006/021929lbl.pdf Label approved 07/21/2006. Available at Accessed August 2, 2006
   Google Scholar
• Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002; 57: 880–884, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332–336, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487–497, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Guest J F, Davie A M, Ruiz F J, Greener M J. Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim Care Respir J 2005; 14: 88–98, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002; 19: 246–251, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Cochrane M G, Bala M V, Downs K E, Mauskopf J, Ben-Joseph R H. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 2000; 117: 542–550, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Newman S P, Busse W W. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002; 96: 293–304, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Nayak A S, Banov C, Corren J, Feinstein B K, Floreani A, Friedman B F, Goldsobel A, Gottschlich G M, Hannaway P J, Lampl K L, Lapidus R J, Lawrence M, Lumry W, Munk Z, Pearlman D, Scardella A T, Schenkel E J, Segal A T, Segall N, Silverman B, Shneyer L, Nolop K B, Harrison J. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol 2000; 84: 417–424, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kemp J P, Berkowitz R B, Miller S D, Murray J J, Nolop K, Harrison J E. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol 2000; 106: 485–492, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bensch G W, Prenner B, Berkowitz R, Galant S, Ramsdell J, Lutsky B. Once-daily evening administration of mometasone furoate in asthma treatment initiation. Ann Allergy, Asthma, Immunol 2006; 96: 533–540, [CSA]
   PubMed Web of Science ®Google Scholar
• Nayak A S, Lampl K L, Segall N, Harrison J E. C96-136 Study Group. Long-term use of once-daily mometasone furoate is effective and well tolerated in patients with mild to moderate persistent asthma. Presented at 57th Annual Meeting of the American Academy of Allergy, Asthma and Immunology, New Orleans, LA, March, 16–212001
   Google Scholar
• Data on file. Schering-Plough, Kenilworth, NJ 1998
   Google Scholar
• Sutherland E R. Nocturnal asthma. J Allergy Clin Immunol 2005; 116: 1179–1186, quiz 1187[INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Martin R J, Banks-Schlegel S. Chronobiology of asthma. Am J Respir Crit Care Med 1998; 158: 1002–1007, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kraft M, Djukanovic R, Wilson S, Holgate S T, Martin R J. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154: 1505–1510, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bernstein D I, Berkowitz R B, Chervinsky P, Dvorin D J, Finn A F, Gross G N, Karetzky M, Kemp J P, Laforce C, Lumry W, Mendelson L M, Nelson H, Pearlman D, Rachelefsky G, Ratner P, Repsher L, Segal A T, Selner J C, Settipane G A, Wanderer A, Cuss F M, Nolop K B, Harrison J E. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 1999; 93: 603–612, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Nathan R A, Nayak A S, Graft D F, Lawrence M, Picone F J, Ahmed T, Wolfe J, Vanderwalker M L, Nolop K B, Harrison J E. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol 2001; 86: 203–210, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Noonan M, Karpel J P, Bensch G W, Ramsdell J W, Webb D R, Nolop K B, Lutsky B N. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol 2001; 86: 36–43, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• D'Urzo A, Karpel J P, Busse W W, Boulet L P, Monahan M E, Lutsky B, Staudinger H. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr Med Res Opin 2005; 21: 1281–1289, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Karpel J P, Busse W W, Noonan M J, Monahan M E, Lutsky B, Staudinger H. Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. Ann Pharmacother 2005; 39: 1977–1983, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• O'Connor B, Bonnaud G, Haahtela T, Luna J M, Querfurt H, Wegener T, Lutsky B. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol 2001; 86: 397–404, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bousquet J, D'Urzo A, Hebert J, Barraza C H, Boulet L P, Suárez-Chaćon R, Harnest U, Lundbäck B, Martinez Morales G, Niemihen M M, Nolop K B, Visser S, Lutsky B N. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J 2000; 16: 808–816, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hebert J, Kunkel G, Neffen H, Laitnen L, Peiffer G, Westbroek J, Tonnel A B, Lutsky B N. The safety and efficacy of mometasone furoate (MF) administered by dry powder inhaler (DPI) in patients previously maintained on high doses of prescribed inhaled corticosteroids (ICS). Presented at the 56th Annual Meeting of the American Academy of Allergy, Asthma and Immunology, San Diego, CA, March, 3–82000
   Google Scholar
• Fish J E, Karpel J P, Craig T J, Bensch G W, Noonan M, Webb D R, Silverman B, Schenkel E J, Rooklin A R, Ramsdell J W, Nathan R, Leflein J G, Grossman J, Graft D F, Gower R G, Garay S M, Frigas E, De Graff A C, Bronsky E A, Bernstein D I, Berger W, Shneyer L, Nolop K B, Harrison J E. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol 2000; 106: 852–860, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Nelson H S, Bernstein I L, Fink J, Edwards T B, Spector S L, Storms W W, Tashkin D P. Oral glucocorticosteroid-sparing effect of budesonide administered by Turbuhaler: a double-blind, placebo-controlled study in adults with moderate-to-severe chronic asthma. Pulmicort Turbuhaler Study Group. Chest 1998; 113: 1264–1271, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Noonan M, Chervinsky P, Busse W W, Weisberg S C, Pinnas J, de Boisblanc B P, Boltansky H, Pearlman D, Repsher L, Kellerman D. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 1995; 152: 1467–1473, (5 Pt. 1)[INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Nelson H S, Busse W W, de Boisblanc B P, Berger W E, Noonan M J, Webb D R, Wolford J P, Mahajan P S, Hamedani A G, Shah T, Harding S M. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J Allergy Clin Immunol 1999; 103: 267–275, (2 Pt. 1)[INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Corren J, Berkowitz R, Murray J J, Prenner B. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int J Clin Pract 2003; 57: 567–572, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wardlaw A, Larivee P, Eller J, Cockroft D W, Ghaly L, Harris A G. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. Ann Allergy Asthma Immunol 2004; 93: 49–55, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• D'Urzo A, Hebert J, Backer V, Ghaly L. Mometasone furoate dry powder inhaler 400 mcg once puff, once daily in the evening compared with budesonide dry powder inhaler 400 mcg twice daily in subjects with asthma previously maintained on budesonide. Presented at the 70th Annual Meeting of the American College of Chest Physicians, Seattle, WA, October, 23–282004
   Google Scholar
• Chervinsky P, Di Bartolo G, Staudinger H. MF-DPI given as one puff once daily in the evening significantly improves HQOL in patients with mild to moderate asthma. Presented at 2003 International Conference of the American Thoracic Society, Seattle, WA, May, 16–212003
   Google Scholar
• Affrime M B, Cuss F, Padhi D, Wirth M, Pai S, Clement R P, Lim J, Kantesaria B, Alton K, Cayen M N. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000; 40: 1227–1236, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Affrime M B, Kosoglou T, Thonoor C M, Flannery B E, Herron J M. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 2000; 118: 1538–1546, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Chrousos G P, Ghaly L, Shedden A, Iezzoni D G, Harris A G. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest 2005; 128: 70–77, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Fardon T C, Lee D K, Haggart K, McFarlane L C, Lipworth B J. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 2004; 170: 960–966, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Leone F T, Fish J E, Szefler S J, West S L. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. Chest 2003; 124: 2329–2340, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Asmanex Twisthaler (mometasone furoate inhalation powder). Schering Corporation, Kenilworth, NJ 2005, Full Prescribing Information
   Google Scholar
• Flovent H FA. (fluticasone propionate). GlaxoSmithKline, Research Triangle Park, NC 2005, Full Prescribing Information
   Google Scholar
• Pulmicort Turbuhaler (budesonide inhalation powder). AstraZeneca Pharmaceuticals LP, Wilmington, DE 2003, Full Prescribing Information
   Google Scholar
• Qvar (beclomethasone dipropionate). IVAX Laboratories, Inc., Miami, FL 2002
   Google Scholar
• Karpel J P. An easy-to-use dry-powder inhaler. Adv Ther 2000; 17: 282–286, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Yang T T, Li S, Wyka B, Kenyon D. Drug delivery performance of the mometasone furoate dry powder inhaler. J Aerosol Med 2001; 14: 487–494, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar